4Nicolas JM.The metabolic profile of second—generation antihistamines[J] .Allergy,2000,55(Suppl 60):46—52.
5Renwick AG.The metabolism of antihistamines and drug interactions:the role of cytochrome P450 enzymes[J]Clin Exp Allergy,1999,29(Suppl 3):1 16—124.
6Taglialatela M,Annunziato L.Evaluation of the cardiac safety of second—generation antihistamines.Allergy,2000,55(Suppl 60):22-30.
7Yap YG,Camm AJ.Arrhythmogenic mechanisms of non—sedating antihistamines[J].Clin Exp Allergy.1999.29(Suppl 3):174—181.
8Timmerman H.Factors involved in the absence of sedative effects by the secondgeneration antihistamines.Allergy,2000,55(Suppl 60):5—10.
9Hindmareh I,Shamsi Z.Antihistamines:models to assess sedative properties,assessment of sedation,safety and other side—effects[J].Clin Exp Allergy,1999,29(Suppl 3):133—142.
10Walsh GM.The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy,2000,55(Suppl 60):53—61.
